Literature DB >> 20610813

Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study.

Sigurdur Y Kristinsson1, Min Tang, Ruth M Pfeiffer, Magnus Björkholm, Cecilie Blimark, Ulf-Henrik Mellqvist, Anders Wahlin, Ingemar Turesson, Ola Landgren.   

Abstract

Patients with multiple myeloma (MM) have an increased risk of fractures. On the basis of small numbers, patients with monoclonal gammopathy of undetermined significance (MGUS) have been reported to have an increased fracture risk. Using population-based data from Sweden, we assessed the risks of fractures in 5326 MGUS patients diagnosed from 1958 to 2006, compared with 20 161 matched controls. MGUS patients had an increased risk of any fracture at 5 (hazard ratio [HR] = 1.74; 95% confidence interval [CI], 1.58-1.92) and 10 (HR = 1.61; 95% CI, 1.49-1.74) years. The risk was significantly higher for axial (skull, vertebral/pelvis, and sternum/costae) compared with distal (arm and leg) fractures (P < .001). On the basis of 10 years of follow-up, there was an increased risk of vertebral/pelvic (HR = 2.37; 95% CI, 2.02-2.78), sternal/costae (HR = 1.93; 95% CI, 1.5-2.48), arm (HR = 1.23; 95% CI, 1.06-1.43), leg (HR = 1.40; 95% CI, 1.26-1.56), and other/multiple fractures (HR = 4.25; 95% CI, 3.29-5.51). Risks for fractures did not differ by isotype or M protein concentration at diagnosis. MGUS patients with (versus without) fractures had no excess risk of MM or Waldenström macroglobulinemia. Our results suggest that bone alterations are present in early myelomagenesis. Our findings may have implications for the development of better prophylaxis for bone disease in MGUS, and they provide novel clues on pathogenesis of MM bone disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20610813      PMCID: PMC3324256          DOI: 10.1182/blood-2010-04-282848

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis.

Authors:  H W Woitge; E Horn; A V Keck; B Auler; M J Seibel; M Pecherstorfer
Journal:  Clin Chem       Date:  2001-04       Impact factor: 8.327

Review 2.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2004-10-28       Impact factor: 91.245

3.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

4.  Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Therese M-L Andersson; Sandra Eloranta; Paul W Dickman; Lynn R Goldin; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

5.  Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).

Authors:  Marianna Politou; Evangelos Terpos; Athanasios Anagnostopoulos; Richard Szydlo; Michael Laffan; Mark Layton; Jane F Apperley; Meletios-Athanasios Dimopoulos; Amin Rahemtulla
Journal:  Br J Haematol       Date:  2004-09       Impact factor: 6.998

6.  Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma.

Authors:  M Laroche; M Attal; C Dromer
Journal:  Clin Rheumatol       Date:  1996-07       Impact factor: 2.980

7.  Fracture risk in monoclonal gammopathy of undetermined significance.

Authors:  L Joseph Melton; S Vincent Rajkumar; Sundeep Khosla; Sara J Achenbach; Ann L Oberg; Robert A Kyle
Journal:  J Bone Miner Res       Date:  2004-01       Impact factor: 6.741

8.  Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma.

Authors:  Christian Jakob; Ivana Zavrski; Ulrike Heider; Brigitte Brux; Jan Eucker; Corinna Langelotz; Pranav Sinha; Kurt Possinger; Orhan Sezer
Journal:  Eur J Haematol       Date:  2002-07       Impact factor: 2.997

9.  Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies.

Authors:  R Bataille; D Chappard; M F Basle
Journal:  Blood       Date:  1996-06-01       Impact factor: 22.113

10.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Authors:  Erming Tian; Fenghuang Zhan; Ronald Walker; Erik Rasmussen; Yupo Ma; Bart Barlogie; John D Shaughnessy
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

View more
  40 in total

Review 1.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

Review 2.  Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Oncology (Williston Park)       Date:  2011-06       Impact factor: 2.990

3.  Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance.

Authors:  Jad G Sfeir; Tito D Pena Guzman; Lucia Bedatsova; Stephen M Broski; Matthew T Drake
Journal:  Bone       Date:  2020-04-28       Impact factor: 4.398

Review 4.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

Review 5.  Precursors to lymphoproliferative malignancies.

Authors:  Lynn R Goldin; Mary L McMaster; Neil E Caporaso
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

Review 6.  unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?

Authors:  Matthew T Drake
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

7.  Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.

Authors:  Sigrun Thorsteinsdottir; Sigrun H Lund; Ebba K Lindqvist; Marianna Thordardottir; Gunnar Sigurdsson; Rene Costello; Debra Burton; Hlif Steingrimsdottir; Vilmundur Gudnason; Gudny Eiriksdottir; Kristin Siggeirsdottir; Tamara B Harris; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Blood Adv       Date:  2017-12-21

Review 8.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

Review 9.  What is the significance of monoclonal gammopathy of undetermined significance?

Authors:  Catherine Atkin; Alex Richter; Elizabeth Sapey
Journal:  Clin Med (Lond)       Date:  2018-10       Impact factor: 2.659

10.  A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.

Authors:  T E Witzig; K M Laumann; M Q Lacy; S R Hayman; A Dispenzieri; S Kumar; C B Reeder; V Roy; J A Lust; M A Gertz; P R Greipp; H Hassoun; S J Mandrekar; S V Rajkumar
Journal:  Leukemia       Date:  2012-08-20       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.